Role of the Keap1/Nrf2 pathway in neurodegenerative diseases

Pathology International

Volumn 65, Issue 5, 2015, Pages 210-219

  Yamazaki, Hiromi ^a   Tanji, Kunikazu ^a   Wakabayashi, Koichi ^a   Matsuura, Shin ^a   Itoh, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Dimethyl fumarate; Neurodegenerative disease; Nrf2; Oxidative stress; ROS

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN P62; PROTEIN TYROSINE KINASE A; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER GROWTH; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AUTOPHAGY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURODEGENERATIVE DISEASES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84927650894     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12261     Document Type: Article

References (77)

1. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: A historical overview. Antioxid Redox Signal 2010; 13: 1665-1678.
2. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 2013; 34: 340-346.
3. Itoh K, Chiba T, Takahashi S etal. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322.
4. Yamazaki H, Katsuoka F, Motohashi H, Engel JD, Yamamoto M. Embryonic lethality and fetal liver apoptosis in mice lacking all three small Maf proteins. Mol Cell Biol 2011; 32: 808-816.
5. Wakabayashi N, Itoh K, Wakabayashi J etal. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003; 35: 238-245.
6. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP. Cellular stress responses, the hormesis paradigm, and vitagenes: Novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 2010; 13: 1763-1811.
7. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A 1996; 93: 13943-13948.
8. Shih AY, Johnson DA, Wong G etal. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003; 23: 3394-3406.
9. Murphy TH, Yu J, Ng R etal. Preferential expression of antioxidant response element mediated gene expression in astrocytes. J Neurochem 2001; 76: 1670-1678.
10. Ahlgren-Beckendorf JA, Reising AM, Schander MA, Herdler JW, Johnson JA. Coordinate regulation of NAD(P)H:Quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurons and glia: Role of the antioxidant/electrophile responsive element. Glia 1999; 25: 131-142.
11. Chen PC, Vargas MR, Pani AK etal. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 2009; 106: 2933-2938.
12. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A 2005; 102: 244-249.
13. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008; 28: 13574-13581.
14. Gan L, Vargas MR, Johnson DA, Johnson JA. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J Neurosci 2012; 32: 17775-17787.
15. Linker RA, Lee DH, Ryan S etal. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134: 678-692.
16. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004; 3: 205-214.
17. Habas A, Hahn J, Wang X, Margeta M. Neuronal activity regulates astrocytic Nrf2 signaling. Proc Natl Acad Sci U S A 2013; 110: 18291-18296.
18. Andersen JK. Oxidative stress in neurodegeneration: Cause or consequence? Nat Med 2004; 10 Suppl: S18-25.
19. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140: 918-934.
20. Ishii T, Itoh K, Takahashi S etal. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-16029.
21. Durchdewald M, Beyer TA, Johnson DA, Johnson JA, Werner S, auf dem Keller U. Electrophilic chemicals but not UV irradiation or reactive oxygen species activate Nrf2 in keratinocytes in vitro and in vivo. J Invest Dermatol 2007; 127: 646-653.
22. Bell KF, Al-Mubarak B, Fowler JH etal. Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. Proc Natl Acad Sci U S A 2011; 108: E1-2.
23. Kobayashi M, Li L, Iwamoto N etal. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 2009; 29: 493-502.
24. Kanninen K, Malm TM, Jyrkkänen HK etal. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci 2008; 39: 302-313.
25. Lee JM, Hanson JM, Chu WA, Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem 2001; 276: 20011-20016.
26. Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T, Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 2006; 339: 915-922.
27. Mitsuishi Y, Taguchi K, Kawatani Y etal. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22: 66-79.
28. Taguchi K, Hirano I, Itoh T etal. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol Cell Biol 2014; 34: 900-913.
29. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305.
30. Muramatsu H, Katsuoka F, Toide K, Shimizu Y, Furusako S, Yamamoto M. Nrf2 deficiency leads to behavioral, neurochemical and transcriptional changes in mice. Genes Cells 2013; 18: 899-908.
31. Hubbs AF, Benkovic SA, Miller DB etal. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 2007; 170: 2068-2076.
32. Geetha T, Jiang J, Wooten MW. Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol Cell 2005; 20: 301-312.
33. Moscat J, Diaz-Meco MT. P62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137: 1001-1004.
34. Yoshikawa Y, Ogawa M, Hain T etal. Listeria monocytogenes ActA-mediated escape from autophagic recognition. Nat Cell Biol 2009; 11: 1233-1240.
35. Lamark T, Johansen T. Aggrephagy: Selective disposal of protein aggregates by macroautophagy. Int J Cell Biol 2012; 2012: 736905.
36. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24: 8055-8068.
37. Myeku N, Figueiredo-Pereira ME. Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: Association with sequestosome 1/p62. J Biol Chem 2011; 286: 22426-22440.
38. Ramesh Babu J, Lamar Seibenhener M, Peng J etal. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 2008; 106: 107-120.
39. Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A 2007; 104: 5205-5210.
40. Kosaka K, Mimura J, Itoh K etal. Role of Nrf2 and p62/ZIP in the neurite outgrowth by carnosic acid in PC12h cells. J Biochem 2010; 147: 73-81.
41. Komatsu M, Kurokawa H, Waguri S etal. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213-223.
42. Ichimura Y, Waguri S, Sou YS etal. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 2013; 51: 618-631.
43. Fan W, Tang Z, Chen D etal. Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 2010; 6: 614-621.
44. Tanji K, Maruyama A, Odagiri S etal. Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. J Neuropathol Exp Neurol 2013; 72: 18-28.
45. Tanji K, Miki Y, Ozaki T etal. Phosphorylation of serine 349 of p62 in Alzheimer's disease brain. Acta Neuropathol Commun 2014; 2: 50.
46. Zhao LN, Lu L, Chew LY, Mu Y. Alzheimer's disease-a panorama glimpse. Int J Mol Sci 2014; 15: 12631-12650.
47. Leuner K, Schütt T, Kurz C etal. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal 2012; 16: 1421-1433.
48. Ramsey CP, Glass CA, Montgomery MB etal. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007; 66: 75-85.
49. Wang Y, Santa-Cruz K, DeCarli C, Johnson JA. NAD(P)H:Quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer's disease. Neurobiol Aging 2000; 21: 525-531.
50. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C. Regional NAD(P)H:Quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 2004; 25: 63-69.
51. Schipper HM, Bennett DA, Liberman A etal. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 2006; 27: 252-261.
52. Eftekharzadeh B, Maghsoudi N, Khodagholi F. Stabilization of transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid beta formation in NT2N neurons. Biochimie 2010; 92: 245-253.
53. Khodagholi F, Eftekharzadeh B, Maghsoudi N, Rezaei PF. Chitosan prevents oxidative stress-induced amyloid beta formation and cytotoxicity in NT2 neurons: Involvement of transcription factors Nrf2 and NF-kappaB. Mol Cell Biochem 2010; 337: 39-51.
54. Wruck CJ, Götz ME, Herdegen T, Varoga D, Brandenburg LO, Pufe T. Kavalactones Protect neural cells against amyloid β peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol Pharmacol 2008; 73: 1785-1795.
55. Frautschy SA, Hu W, Kim P etal. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22: 993-1005.
56. Kanninen K, Heikkinen R, Malm T etal. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 16505-16510.
57. Jo C, Gundemir S, Pritchard S, Jin YN, Rahman I, Johnson GV. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat Commun 2014; 5: 1-13.
58. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew Chem Int Ed Engl 2013; 52: 3511-3515.
59. Crowe A, James MJ, Lee VM etal. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem 2013; 288: 11024-11037.
60. Landhuis E. Will tau drug show its true colors in phase 3 trials? International Conference on Frontotemporal Dementias 2012. Alzforum, 2012. (Accessed 6 February 2015.) Available from: http://www.alzforum.org/news/research-news/will-tau-drug-show-its-true-colors-phase-3-trials.
61. Stack C, Jainuddin S, Elipenahli C etal. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet 2014; 23: 3716-3732.
62. Cattaneo A, Calissano P. Nerve growth factor and Alzheimer's disease: New facts for an old hypothesis. Mol Neurobiol 2012; 46: 588-604.
63. Mimura J, Kosaka K, Maruyama A etal. Nrf2 regulates NGF mRNA induction by carnosic acid in T98G glioblastoma cells and normal human astrocytes. J Biochem 2011; 150: 209-217.
64. Hattori N, Saiki S, Imai Y. Regulation by mitophagy. Int J Biochem Cell Biol 2014; 53: 147-150.
65. Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013; 22: 11-17.
66. Lastres-Becker I, Ulusoy A, Innamorato NG etal. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet 2012; 21: 3173-3192.
67. Van Muiswinkel FL, de Vos RA, Bol JG etal. Expression of NAD(P)H:Quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004; 25: 1253-1262.
68. Innamorato NG, Jazwa A, Rojo AI etal. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS ONE 2010; 5: e11838.
69. Johnson DA, Andrews GK, Xu W, Johnson JA. Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem 2002; 81: 1233-1241.
70. Jakel RJ, Kern JT, Johnson DA, Johnson JA. Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. Toxicol Sci 2005; 87: 176-186.
71. Jakel RJ, Townsend JA, Kraft AD, Johnson JA. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007; 1144: 192-201.
72. Rojo AI, Innamorato NG, Martín-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010; 58: 588-598.
73. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003; 278: 37948-37956.
74. Burton NC, Kensler TW, Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006; 27: 1094-1100.
75. Satoh T, Harada N, Hosoya T, Tohyama K, Yamamoto M, Itoh K. Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice. Biochem Biophys Res Commun 2009; 380: 298-302.
76. Arnold P, Mojumder D, Detoledo J, Lucius R, Wilms H. Pathophysiological processes in multiple sclerosis: Focus on nuclear factor erythroid-2-related factor 2 and emerging pathways. Clin Pharmacol 2014; 6: 35-42.
77. Ellrichmann G, Petrasch-Parwez E, Lee DH etal. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE 2011; 6: e16172.